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Abstract: Polycythemia vera (PV) is a myeloproliferative neoplasm marked by hyperproliferation of the
myeloid lineages and the presence of an activating JAK2 mutation. Hydroxyurea (HU) is a standard treat-
ment for high-risk patients with PV. Because disease-driving mechanisms are thought to arise in PV stem
cells, effective treatments should target primarily the stem cell compartment. We tested for the antipro-
liferative effect of patient treatment with HU in fluorescence-activated cell sorting-isolated hematopoietic
stem/multipotent progenitor cells (HSC/MPPs) and more committed erythroid progenitors (common
myeloid/megakaryocyte-erythrocyte progenitors [CMP/MEPs]) in PV using RNA-sequencing and gene
set enrichment analysis. HU treatment led to significant downregulation of gene sets associated with cell
proliferation in PV HSCs/MPPs, but not in PV CMP/MEPs. To explore the mechanism underlying
this finding, we assessed for expression of solute carrier membrane transporters, which mediate trans-
membrane movement of drugs such as HU into target cells. The active HU uptake transporter OCTN1
was upregulated in HSC/MPPs compared with CMP/MEPs of untreated patients with PV, and the HU
diffusion facilitator urea transporter B (UTB) was downregulated in HSC/MPPs compared with CM-
P/MEPs in all patient and control groups tested. These findings indicate a higher accumulation of HU
within PV HSC/MPPs compared with PV CMP/MEPs and provide an explanation for the differential
effects of HU in HSC/MPPs and CMP/MEPs of patients with PV. In general, the findings highlight the
importance of transporter expression in linking therapeutics with human disease.
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Polycythemia vera (PV) is a myeloproliferative neoplasm marked by hyperproliferation
of the myeloid lineages and the presence of an activating JAK2 mutation. Hydroxyurea
(HU) is a standard treatment for high-risk patients with PV. Because disease-driving
mechanisms are thought to arise in PV stem cells, effective treatments should target
primarily the stem cell compartment. We tested for the antiproliferative effect of
patient treatment with HU in fluorescence-activated cell sorting-isolated hematopoietic
stem/multipotent progenitor cells (HSC/MPPs) and more committed erythroid progeni-
tors (common myeloid/megakaryocyte−erythrocyte progenitors [CMP/MEPs]) in PV
using RNA-sequencing and gene set enrichment analysis. HU treatment led to signifi-
cant downregulation of gene sets associated with cell proliferation in PV HSCs/MPPs,
but not in PV CMP/MEPs. To explore the mechanism underlying this finding, we
assessed for expression of solute carrier membrane transporters, which mediate trans-
membrane movement of drugs such as HU into target cells. The active HU uptake
transporter OCTN1 was upregulated in HSC/MPPs compared with CMP/MEPs of
untreated patients with PV, and the HU diffusion facilitator urea transporter B (UTB)
was downregulated in HSC/MPPs compared with CMP/MEPs in all patient and control
groups tested. These findings indicate a higher accumulation of HU within PV HSC/
MPPs compared with PV CMP/MEPs and provide an explanation for the differential
effects of HU in HSC/MPPs and CMP/MEPs of patients with PV. In general, the find-
ings highlight the importance of transporter expression in linking therapeutics with
human disease. © 2021 ISEH – Society for Hematology and Stem Cells. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/)
Polycythemia vera (PV) is a myeloproliferative neoplasm
characterized by hyperproliferation of the erythroid, mega-
karyocytic, and granulocytic lineages and the presence of an
activating mutation in JAK2 [1−6]. Clinically, PV is
marked by erythrocytosis and a concomitant increase in the
risk of thrombotic events [1]. Disease-driving pathogenic
changes are thought to arise in stem cells that give rise to
the diseased cell clone [7−9]. In healthy individuals,
hematopoietic stem/multipotent progenitor cells (HSC/
MPPs) can differentiate into committed progenitor cells,
including common myeloid/megakaryocyte-erythrocyte pro-
genitors (CMP/MEPs) [10−12]. When the HSC differentia-
tion process is changed, for example, upon genetic or
epigenetic alterations in HSCs, abnormal stem cell subpopu-
lations may form, leading to clonal hematopoiesis and the
onset of myeloid disease [13,14].
Treatment of PV is aimed at the prevention of throm-
botic events [1], and typical frontline management includes
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a combination of low-dose aspirin and phlebotomy to
decrease hematocrit to <45% [15,16]. For high-risk
patients with PV, cytoreductive therapy with hydroxyurea
(HU) is a standard treatment against cardiovascular com-
plications [17]. HU acts as a potent ribonucleotide reduc-
tase inhibitor and inhibits cell proliferation by diminishing
intracellular ribonucleotide pools [18,19]. This antiprolifer-
ative effect of HU is dependent on active uptake of HU
into the hyperproliferating PV hematopoietic stem and pro-
genitor cells. The transmembrane movement of HU is
mediated by solute carrier membrane transporters, such as
OCTN1 (organic cation transporter, novel, type1,
SLC22A4), OCTN2 (organic cation transporter, novel,
type2, SLC22A5), UTA (urea transporter A, SLC14A2),
UTB (urea transporter B, SLC14A1), OATP1A2 (organic
anion transporting polypeptide 1A2, SLCO1A2), OATP1B1
(organic anion-transporting polypeptide 1B1, SLCO1B1),
and OATP1B3 (organic anion-transporting polypeptide
1B3, SLCO1B3) [20]. Systematic research on these and
other solute carrier membrane transporters is deemed
essential to link therapeutics with human disease [21].
Furthermore, HU transporter expression has not been
assessed in disease-initiating HSC/MPPs and more com-
mitted progenitor cells in patients with PV. We thus per-
formed RNA-sequencing experiments with quantitative
polymerase chain reaction (qPCR) validation in HSC/
MPPs and CMP/MEPs of untreated and HU-treated
chronic and progressed patients with PV, as well as con-
trols, to assess potential differential effects of HU and
HU transporter expression in PV hematopoietic stem
and progenitor cell subpopulations.
Methods
Human hematopoietic stem/progenitor cell samples
Fresh human peripheral blood samples were collected from
untreated patients with PV, patients with PV treated with
HU, and controls with phlebotomy-requiring hemochromato-
sis during clinical routine phlebotomy appointments (Depart-
ment of Medical Oncology and Hematology, University
Hospital Zurich, Zurich, Switzerland) (Table 1). All samples
were collected with informed consent, and the experiments
were approved by the responsible local ethics committee
(Kanton Zurich, Switzerland).
To obtain the required cell numbers for the different hemato-
poietic stem and progenitor cell subpopulations, 0.4−3.6 L of
blood had to be collected from individual patients in consecutive
settings within periods of a few months. Because such volumes
cannot be retrieved from individual healthy donors, we recruited
hemochromatosis patients that are physically healthy and receive
regular phlebotomies as control subjects.
Cell preparation, flow-cytometric analysis, cell sorting, and
sample preparation for RNA-sequencing
Human hematopoietic stem cell-enriched subfractions and ery-
throid progenitors were isolated using fluorescence-activated cell
sorting (FACS) as previously described [22] and depicted in
Figure 1. In brief, mononuclear cells were isolated using Ficoll
gradient centrifugation (VWR, Dietikon, Switzerland). CD34+
hematopoietic stem and progenitor cells were then enriched from
mononuclear cells using immunomagnetic beads according to the
manufacturer’s instructions (CD34 MicroBead Kit; Miltenyi
Biotec, Bergisch Gladbach, Germany) and viably frozen. After
thawing, HSC/MPPs and CMP/MEPs were isolated by FACS
from CD34+-enriched cells using anti-hCD34, anti-hCD38,
anti-hCD123, anti-hCD45RA, and 12 antibodies against line-
age markers (anti-hCD2, anti-hCD3, anti-hCD4, anti-hCD7,
anti-hCD8, anti-hCD10, anti-hCD11b, anti-hCD14, anti-
hCD19, anti-hCD20, anti-hCD56, anti-hCD235a). A complete
list of the antibodies used is provided in Supplementary Table
E1 (online only, available at www.exphem.org). Up to
10,000 HSC/MPPs and CMP/MEPs were sorted into RNeasy
lysis buffer (Qiagen, Hilden, Germany) with b-mercaptoetha-
nol for subsequent RNA-sequencing experiments.
RNA isolation and sequencing
Total RNA was isolated and purified according to the man-
ufacturer’s instructions using the RNeasy Plus Micro Kit
(Qiagen, Hilden, Germany). RNA sequencing was performed
as delineated in Picelli et al. [23] using the NovaSeq
sequencing platform (Illumina, San Diego, CA).
RNA-sequencing data analysis
Adapters and low-quality tails were trimmed from reads before
the reads were mapped to the transcriptome. STAR aligner (Ver-
sion 2.6.1.c) [24] was employed to align the RNA-sequencing
data to Ensembl Release 91 reference genome build GRCh38.
p10. Gene expression values were determined using feature-
Counts from the Bioconductor package Rsubread (Version
1.32.4) [25]. Differential gene expression was calculated with
DESeq2 package (Version 1.22.2) [26].
Mutational analysis from RNA-sequencing data
We followed the GATK Best Practices Workflow [27].
Mapped RNA reads were duplicates marked, split, and base
quality recalibrated. Variants were called by HaplotypeCaller
from GATK (Version 4.0.8.1) [27] and annotated with
Ensembl VEP [28]. We tested for the JAK2 V617F mutation
and estimated its allele burden.
Variant allele frequency determination in granulocytes using
droplet digital PCR
Granulocytes were collected from patients with PV using
centrifugation and treatment with 150 mM NH4Cl/10 mM
KHCO3/0.1 mM Na2EDTA to remove contaminating erythro-
cytes. Genomic DNA was extracted with the QIAamp DNA
Mini Kit (Qiagen) according to the manufacturer’s instruc-
tions. Droplet digital PCR (ddPCR) for JAK2-V617F variant
allele frequency determination was performed with the Bio-
Rad QX200 ddPCR system and the assay dHsaMDV2010061
(BioRad, Hercules, CA) using the manufacturer’s protocol.
Gene ontology enrichment analysis
Gene sets for gene set enrichment analysis were retrieved
from the Gene Ontology Consortium database (www.geneon
tology.org) on May 26, 2019. Ranked lists were built from
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Table 1. Characteristics of patients with PV and controls
Group Subgroups
combined











PV PVchronUT PV5* 59 M PV 2 20%/70% 43% ASA
PV PVchronUT PV6 53 M PV 5 70%/100% 93% ASA
PV PVchronUT PV8 68 F PV 1 0%/80% ASA, BP, statin
PV PVchronUT PV13 55 M PV 5 100%/100% 78% ASA, BP
PV PVchronUT PV14 44 F PV 1 n.a./100% 97% ASA, anti-depressant
PV PVchronUT PV16 50 M PV 6 0%/50% 43% ASA
PV PVprogUT PV17 64 M Post-PV MF 1 80%/100% BP, anti-uric, prednisone
PV PVprogUT PV18 72 F PV transforming
into MF
2 100%/100% 98% ASA, BP, anti-uric
PV PVchronHU PV2 65 M PV 8 0%/0% (GMPs:
20%)
HU, ASA, BP, statin
PV PVchronHU PV3 77 M PV 9 80%/50% 95% HU, ASA, BP
PV PVchronHU PV4 57 M PV 7 0%/n.a. 4% HU, ASA, BP
PV PVchronHU PV5 60 M PV 5 45%/25% 43% HU, ASA
PV PVprogHU PV10 65 M PV transforming
into AML
5 75%/70% HU, ASA
PV PVprogHU PV11 61 M Post-PV MF 1 60%/100% 99% HU, ASA
PV PVprogHU PV15 82 M Post-PV MF 1 100%/50% HU, phenprocoumon
, anti-uric
Control Control CON1 71 M Hemochromatosis 8 0%/0% BP
Control Control CON2 42 M Hemochromatosis 3 0%/0% None
Control Control CON2 66 M Hemochromatosis 3 0%/0% ASA, BP, anti-
depressant
Control Control CON2 61 F Hemochromatosis 1 0%/0% Inhal
Control Control CON2 40 M Hemochromatosis 2 0%/0% none
Control Control CON3 54 M Hemochromatosis 9 0%/0% ASA, anti-diabetic
Control Control CON4 45 M Hemochromatosis 3 0%/0% Thyroxine
Control Control CON4 60 F Hemochromatosis 3 0%/0% BP, HRT
Control Control CON5 63 M Hemochromatosis 8 0%/0% Statin
AML=Acute myeloid leukemia; anti-uric=uric acid-lowering medication; ASA=acetylsalicylic acid; BP=blood pressure medication; F=female; GMP=granulocyte−macrophage progenitors;
HRT=hormone replacement therapy; HU=under treatment with hydroxyurea; Inhal=inhalative medication; M=male; MF=myelofibrosis; n.a.=not available; UT=untreated.
























































the normalized and filtered transcriptome data using log2
(fold change) as ranking criterion. Only RNAs expressed in
at least half of the replicates in both comparison groups were
considered. Gene set enrichment analysis was run on pre-
ranked lists using Version 4.1.0 of the software (http://www.
broadinstitute.org/gsea) with default settings [29]. Signifi-
cance was defined stringently by a false discovery rate
(FDR) <0.05.
Quantitative polymerase chain reaction
Isolated mRNA was reverse transcribed using the SuperScript
IV VILO Master Mix with ezDNase enzyme (SuperScript IV
Vilo Master Mix with ezDNase Enzyme, ThermoFisher Sci-
entific, Waltham, MA) according to the manufacturer’s
instructions. Quantitative analysis of cDNA was performed
employing Taqman probes and master mix (TaqMan Fast
Advanced Master Mix, ThermoFisher Scientific). Individual
probes included Hs00998199_m1 (UTB, SLC14A1),
Hs00268200_m1 (OCTN1, SLC22A4), and Hs99999903_m1
(ACTB) (ThermoFisher Scientific). ACTB was used as
housekeeping control gene. Expression values were derived
using a DCt approach.
Additional statistical analyses
Statistical significance of RNA expression between different
patient and control groups and between HSC/MPPs and
CMP/MEPs was determined by two-way analysis of variance
and fitted mixed model analyses, correcting for multiple test-
ing using the Tukey method, and by multiple t tests using
the Holm-Sidak method for correction for multiple testing.
Regression analyses were performed based on ordinary least-
squares estimation. Principal component analysis was per-
formed on FPKM (fragments per kilobase of transcript per
million mapped reads) expression values using the prcomp
function in R.
Data availability
The transcriptomics data have been deposited to the gene
expression omnibus (GEO) repository under accession num-
ber GSE145802.
Results
Treatment with HU has differential effects on HSC/
MPPs compared with CMP/MEPs of patients with PV
To study the molecular effects of treatment with HU in
undifferentiated stem/multipotent progenitor cells and
more committed erythroid progenitors of patients with
PV, we determined the transcriptomic profiles of HSC/
MPPs and CMP/MEPs isolated from 99 blood samples
of 8 untreated patients with PV, 7 HU-treated patients
with PV, and 9 controls. Consecutive samples from the
same individual patients had to be pooled to ensure
adequate cell numbers in the different FACS-isolated
hematopoietic stem and progenitor cell subpopulations.
In two instances, blood samples from different control
individuals had to be pooled to maintain constant input
cell numbers (10,000 cells). An average of 14,272
RNAs per individual sample were identified.
Figure 1. FACS isolation of hematopoietic stem and progenitor cell subpopulations from patients with PV and controls. Intact cells were
selected on the basis of forward scatter/side scatter (FSC/SSC). Doublets were excluded using area and height of FSC (FSC-A and FSC-H).
Lymphatic and differentiated cells were excluded using a combination of 12 lineage antibodies. The stem and progenitor cell markers CD34 and
CD38 were employed to select stem cell-enriched cells (Lin−CD34+CD38−) and myeloid progenitor cells (Lin−CD34+CD38+). Stem cell-
enriched cells were further purified to hematopoietic stem and multipotent progenitor cells (HSC/MPPs) using CD45RA. Myeloid progenitor
cells were subdivided into common myeloid progenitors (CMPs), megakaryocyte−erythrocyte progenitors (MEPs), and granulocyte−macrophage
progenitors (GMPs) using the markers CD123 and CD45RA. HSC/MPPs and CMP/MEPs were sorted in uniform cell numbers for downstream
analyses.
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A detailed overview of patient characteristics and
sample distributions is provided in Table 1. The major-
ity of patients with PV and controls studied were male
(80% of PV patients and 78% of controls). The average
ages of patients with PV and controls at times of sam-
ple collection were similar (62 years for PV patients
and 56 years for controls). If patients with PV were
diagnosed with myelofibrosis or acute myeloid leuke-
mia within 1 year after sample collection and were in a
transition state at the time of sampling, they were
referred to as progressed PV (PVprog) as opposed to
chronic PV (PVchron). The overall gene expression
profile of progressed and more severe patients with PV
was similar to that of chronic PV patients
(Supplementary Figure E1, online only, available at
www.exphem.org). At the time of sample collection, 7
of the 15 PV patients studied received HU treatment.
Thereby, only patients that clinically responded to HU
were included in the study. All patients with PV (but
no controls) carried the JAK2 V617F mutation. Allele
burdens varied between 4% and 100%. Different allele
burdens were observed in HSC/MPPs, CMP/MEPs, and
granulocytes, with consistently higher allele burdens
seen in more differentiated CMP/MEPs compared with
HSC/MPPs in untreated patients with PV, but not in
HU-treated patients (Table 1).
To examine the impact of polycythemia vera and
patient treatment with HU on cell proliferation path-
ways, gene set enrichment analysis was performed for
the gene ontologies of DNA replication and G1/S tran-
sition of the mitotic cell cycle. Significant upregulation
of these pathways was seen both in HSC/MPPs and
CMP/MEPs of untreated patients with PV compared
with controls (Figure 2), suggesting increased hemato-
poietic stem and progenitor cell proliferation in
untreated patients with PV. Patient treatment with HU
resulted in strong and highly significant downregulation
of the DNA replication and G1/S transition of the
mitotic cell cycle pathways in PV HSC/MPPs. In con-
trast and using a stringent cutoff of FDR = 0.05, in
CMP/MEPs no significant downregulation of the DNA
replication and G1/S transition of the mitotic cell cycle
gene ontologies was observed (Figure 2). In summary,
patient treatment with HU had a strong negative effect
on cell proliferation pathways in undifferentiated HSC/
MPPs, but not in more committed erythroid progenitors
(CMP/MEPs).
Expression of solute carrier membrane transporters in
HSC/MPPs and CMP/MEPs of patients with PV
Possible reasons for the differential effect of patient
HU treatment in PV HSC/MPPs and PV CMP/MEPs
include the differential expression of solute carrier
membrane transporters. We thus tested for the expres-
sion of solute carrier membrane transporters in HSC/
MPPs and CMP/MEPs of patients with PV and controls
(Figure 3). Among the 57 solute carrier membrane
transporters studied, 29 were expressed in PV and nor-
mal hematopoietic stem and progenitor cell samples.
Most of these solute carrier membrane transporters
were equally expressed in PV and normal hematopoi-
etic stem and progenitor cell subpopulations. Excep-
tions included the monocarboxylate transporter MCT4,
the peptide transporter PEPT2, and the organic cation
and HU transporter OCTN1, with PEPT2 and OCTN1
being more highly expressed in PV HSC/MPPs and
Figure 2. Effect of PV and patient treatment with HU on cell proliferation gene ontologies in different PV hematopoietic stem and progenitor
cell subpopulations. Upregulated gene ontologies are marked in red, and downregulated gene ontologies are marked in blue. Significance
(FDR = 0.05) is marked by dotted lines. PV.UT=PV patients without HU treatment; PV.HU=PV patients treated with HU; NES=normalized
enrichment score.
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MCT4 being more highly expressed in both PV HSC/
MPPs and PV CMP/MEPs compared with controls
(Figure 3). Among the known HU transporters,
OCTN1, OCTN2, UTB, and, to a reduced extent, UTA
and OATP1B3 were expressed in hematopoietic stem
and progenitor cells of patients with PV and controls.
The HU transporters OATP1A2 and OATP1B1 were
expressed neither in PV nor in control hematopoietic
stem and progenitor cells (Figures 3 and 4). Detailed
explanations of all solute carrier membrane transporters
Figure 3. Expression of solute carrier membrane transporters based on RNA-sequencing data in PV and control hematopoietic stem and progen-
itor cell subpopulations. Denoted are the solute carrier genes encoding individual membrane transporters (in parentheses). Arrows mark HU
transporters. Detailed information on all genes listed is provided in Supplementary Table E2 (online only, available at www.exphem.org) and
under http://slc.bioparadigms.org/.
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studied are provided in Supplementary Table E2
(online only, available at www.exphem.org) and at
http://slc.bioparadigms.org/.
Differential expression of the HU transporter OCTN1
and HU diffusion facilitator UTB in HSC/MPPs and
CMP/MEPs of patients with PV
We next compared HU transporter expression in the
hematopoietic stem and progenitor cell subpopulations
of controls and different PV patient groups (Figure 4).
Differential expression was observed for the active HU
transporter OCTN1 but not for OCTN2 and UTA
(Figure 4A−C). For the HU diffusion facilitator UTB,
significant expression changes were observed between
different hematopoietic stem and progenitor cell subpo-
pulations (Figure 4D), whereas no significant expres-
sion differences were seen for the active HU
transporter OATP1B3 (Figure 4E). OCTN1 expression
Figure 4. Expression of HU transporters based on RNA-sequencing data in different PV patient/control groups and hematopoietic stem and pro-
genitor cell subpopulations. As OCTN1 correlated with hematocrit, its expression was examined in PVchron.UT patients with a hematocrit
≥10% above the normal lower limit. Expression of the other transporters was examined independently of the hematocrit in all patients. Expres-
sion changes in HSC/MPPs and CMP/MEPs of controls, untreated patients with chronic PV, and HU-treated patients with chronic PV were vali-
dated by qPCR (see Supplementary Figure E2). *Adjusted p < 0.05. **Adjusted p < 0.01. ***Adjusted p < 0.001. Error bars represent standard
errors.
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correlated with hematocrit levels (R2=0.537) [30], and
we identified a significant increase in OCTN1 expres-
sion in HSC/MPPs of untreated patients with chronic
PV with hematocrits ≥10% above the normal lower
limit compared with CMP/MEPs in the same patient
group and also compared with HSC/MPPs of HU-
treated patients with chronic PV, patients with pro-
gressed PV, and controls (Figure 4A). In contrast, UTB
was preferentially expressed in CMP/MEPs compared
with HSC/MPPs in all patient and control groups tested
(Figure 4D). These OCTN1 and UTB expression pat-
terns in HSC/MPPs and CMP/MEPs of patients with
PV and controls were validated using an orthogonal
methodology (qPCR) (Supplementary Figure E2, online
only, available at www.exphem.org).
All patients with PV analyzed carried the JAK2
V617F mutation (Table 1), yet expression of OCTN1
and UTB did not correlate with JAK2 V617F allele
burden (R2 = 0.083 and 0.098, respectively). Upregula-
tion of OCTN1 in HSC/MPPs of untreated patients
with PV is thus a JAK2 V617F allele burden-indepen-
dent disease manifestation. Whereas OCTN1 is an
active HU uptake transporter, UTB is a mediator of
bidirectional facilitated HU diffusion [20,31]. Differen-
tial expression of OCTN1 and UTB in HSC/MPPs and
CMP/MEPs of patients with PV can explain the differ-
ential effects of patient treatment with HU in the two
hematopoietic stem and progenitor cell subpopulations.
Discussion
This study identified differential expression of the HU
transporters OCTN1 and UTB in HSC/MPPs and CMP/
MEPs of patients with PV as a possible explanation for
the observed differential effects of HU on cell prolifer-
ation pathways in different PV hematopoietic stem and
progenitor cell subpopulations.
Examining the effect of HU in different hematopoi-
etic stem and progenitor cell subpopulations in PV
patients and controls, we observed a strong inhibitory
effect of HU on activated cell proliferation pathways in
PV HSC/MPPs but not in PV CMP/MEPs. We next
assessed for the expression of 57 different solute car-
rier membrane transporters [21] in HSC/MPPs and
CMP/MEPs of untreated and HU-treated patients with
PV as well as controls and identified upregulation of
the HU uptake transporter OCTN1 in PV HSC/MPPs
compared with PV CMP/MEPs and controls. OCTN1
expression was previously reported in normal myeloid
cells of the erythroid lineage [32] and found to corre-
late with proliferation and the efficacy of HU treatment
in vitro [30,31]. PV is an in vivo proliferation model,
and in line with the in vitro observations, we saw the
highest expression of OCTN1 in HSC/MPPs of
untreated patients with PV and, thus, in the group that
showed activation of proliferation pathways and the
strongest inhibitory effect of HU. OCTN1 is a pH-
dependent transporter [33]. Although in murine
hematopoietic stem and progenitor cells, intracellular
pH was found to be similar to the pH of blood plasma,
increased intracellular pH values were observed with
increased proliferation activity of hematopoietic stem
and progenitor cells [34]. These previous observations
underscore the importance of high OCTN1 expression
in highly proliferating HSC/MPPs of untreated patients
with PV (Figure 4A).
In addition to upregulated OCTN1, we identified
downregulation of UTB expression in HSC/MPPs com-
pared with CMP/MEPs in patients with PV and con-
trols (Figure 4D). Because UTB transports HU
bidirectionally via facilitated diffusion [20], its high
expression prevents intracellular accumulation of HU.
Facilitated diffusion of HU depends on the electro-
chemical gradient across the cell membrane, which was
measured at −12mV in red blood cells [35]. This elec-
trochemical gradient is small compared with those of
other cell types (e.g., −70 to −80mV in neurons).
Assuming a similarly low electrochemical gradient in
hematopoietic stem and progenitor cells, a weak inward
flux of hydroxyurea via UTB is expected at low intra-
cellular HU concentrations, whereas high intracellular
HU concentrations favor the outward flux of hydroxy-
urea through UTB.
mRNA does not always predict solute carrier protein
levels. For soluble proteins, we observed positive
mRNA−protein correlations for 70% of all identified
proteins [22,36]. This overall positive correlation of
protein and RNA expression in hematopoietic stem and
progenitor cells of patients with PV and controls sug-
gests that RNA levels are a reasonable approximate
substitute for protein expression. This study is a first
step in determining possible drug uptake mechanisms
for hydroxyurea in PV HSC/MPPs.
Our study suggests that OCTN1 expression may pre-
dict patients’ response to hydroxyurea. However, we do
not know the response of the untreated patients with
PV to HU, and we thus cannot exclude the possibility
of compensatory mechanisms that may reduce the
expression of OCTN1 in HU-treated patients without
impairing the proliferation response. Prospective stud-
ies correlating the expression of OCTN1 with patients’
response to HU are warranted. Furthermore, the
hematopoietic stem and progenitor cells analyzed in
the study were isolated from the peripheral blood. It
remains to be determined whether similar expression
changes exist in bone marrow hematopoietic stem and
progenitor cells.
In summary, high OCTN1 expression and low UTB
expression favor intracellular accumulation of HU in PV
HSC/MPPs, whereas low OCTN1 expression favors low
intracellular HU levels in PV CMP/MEPs. Hence, our
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findings of differential expression of OCTN1 and UTB
in PV HSC/MPPs and PV CMP/MEPs could well
explain the differential effects of HU on cell prolifera-
tion pathways in these two PV hematopoietic stem and
progenitor cell subpopulations. Overall, our results high-
light the importance of transporter expression in linking
therapeutics with human disease.
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Supplementary Figure 1. Principal component analysis in all PV
samples analyzed. Samples from chronic (PVchron) and more severe
and progressed (PVprog) PV patients demonstrated comparable over-
all gene expression profiles with no apparent outliers observed.
Supplementary Figure 2. qPCR validation of OCTN1 and UTB expression in HSC/MPPs and CMP/MEPs of untreated and HU-treated chronic
PV patients and controls. Shown are fold changes of RNA expression where fold change was defined as 2^Delta(DeltaCt) and Delta(Del-
taCt) = (Ct(beta-actin house keeping gene in a specific sample)-Ct(test gene in same specific sample)) - Mean(Ct(beta-actin house keeping gene
in Control.HSC/MPP)-Ct(test gene in Control.HSC/MPP)). n=9, error bars represent standard errors. ***Adjusted p < 0.001. Abbreviations:
OCTN1= organic cation transporter, novel, type1; UTB= urea transporter B; PVchron. UT = patients with chronic PV without cytoreductive
therapy; PVchron.HU = chronic PV patients with HU treatment.
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Supplementary Table 1.
Antibody Clone Provider Order number
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD2 S5.5 ThermoFisherScientific-Invitrogen CD0206
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD3 7D6 ThermoFisherScientific-Invitrogen MHCD03065
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD4 S3.5 ThermoFisherScientific-Invitrogen MHCD0406
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD7 CD7-6B7 ThermoFisherScientific-Invitrogen MHCD0706
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD8 3B5 ThermoFisherScientific-Invitrogen MHCD0806
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD14 TuK4 ThermoFisherScientific-Invitrogen MHCD1406
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD19 SJ25-C1 ThermoFisherScientific-Invitrogen MHCD1906
Tricolor/phycoerythrin (PE)-Cy5-conjugated anti-hCD56 MEM-188 ThermoFisherScientific-Invitrogen MHCD5606
Phycoerythrin (PE)-Cy5 anti-hCD10 HI10a BioLegend 312206
Phycoerythrin (PE)-Cy5 anti-hCD11b ICRF44 BioLegend 301308
Phycoerythrin (PE)-Cy5 anti-hCD20 2H7 BioLegend 302308
Phycoerythrin (PE)-Cy5 anti-hCD235a GA-R2 BD Biosciences 559944
PE-Cy7-conjugated anti-hCD34 8G12 BD Biosciences 348811
FITC-conjugated anti-hCD38 HIT2 BD Biosciences 555459
APC-conjugated anti-hCD123 6H6 ThermoFisherScientific-Invitrogen 17-1239-42
APC780-conjugated anti-hCD45RA HI100 ThermoFisher Scientific-Invitrogen 47-0458-41
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Supplementary Table 2.
Suppl Table 2
Gene name Full gene name Protein name Full protein name Function (as defined by UniProtKB/Swiss-Prot)
SLC2A4 Solute Carrier Family 2 Member 4 GLUT4 Glucose Transporter Type 4 Insulin-regulated facilitative glucose transporter
SLC2A5 Solute Carrier Family 2 Member 5 GLUT5 Glucose Transporter Type 5 Fructose transporter
SLC5A8 Solute Carrier Family 5 Member 8 SMCT1 Sodium-Coupled Monocarboxylate
Transporter 1
Electrogenic sodium-coupled solute transporter for transport of
monocarboxylates
SLC5A12 Solute Carrier Family 5 Member 12 SMCT2 Sodium-Coupled Monocarboxylate
Transporter 2
Electroneutral sodium-coupled solute transporter for transport of
monocarboxylates
SLC6A6 Solute Carrier Family 6 Member 6 TAUT Taurine Transporter Sodium-dependent taurine and beta-alanine transporter
SLC7A5 Solute Carrier Family 7 Member 5 LAT1 L-Type Amino Acid Transporter 1 Sodium-independent transporter for large neutral amino acids
SLC10A1 Solute Carrier Family 10 Member 1 NTCP Na+/Taurocholate Cotransporting
Polypeptide
Hepatic sodium/bile-acid transporter
SLC10A2 Solute Carrier Family 10 Member 2 ASBT Apical Sodium-Dependent Bile Acid
Transporter
Sodium-dependent reabsorption of bile acids from small intestine
SLC14A1 Solute Carrier Family 14 Member 1 UTB Urea Transporter 1 Urea channel that facilitates transmembrane urea transport down a
concentration gradient
SLC14A2 Solute Carrier Family 14 Member 2 UTA Urea Transporter 2 Specialized low-affinity vasopressin-regulated urea transporter
SLC15A1 Solute Carrier Family 15 Member 1 PEPT1 Peptide Transporter 1 Proton-coupled intake of oligopeptides of 2 to 4 amino acids
SLC15A2 Solute Carrier Family 15 Member 2 PEPT2 Peptide Transporter 2 Proton-coupled intake of oligopeptides of 2 to 4 amino acids
SLC15A3 Solute Carrier Family 15 Member 3 PHT2 Peptide/Histidine Transporter 2 Proton oligopeptide cotransporter
SLC15A4 Solute Carrier Family 15 Member 4 PHT1 Peptide/Histidine Transporter 1 Proton oligopeptide cotransporter
SLC16A1 Solute Carrier Family 16 Member 1 MCT1 Monocarboxylate Transporter 1 Proton-coupled monocarboxylate transporter
SLC16A3 Solute Carrier Family 16 Member 3 MCT4 Monocarboxylate Transporter 3 Proton-linked monocarboxylate transporter
SLC16A7 Solute Carrier Family 16 Member 7 MCT2 Monocarboxylate Transporter 2 Proton-coupled monocarboxylate transporter
SLC19A1 Solute Carrier Family 19 Member 1 RFC Reduced Folate Carrier Protein Transporter that mediates the import of reduced folates and a subset
of cyclic dinucleotides
SLC22A1 Solute Carrier Family 22 Member 1 OCT1 Organic Cation Transporter 1 Translocates a broad array of organic cations with various structures
and molecular weights
SLC22A2 Solute Carrier Family 22 Member 2 OCT2 Organic Cation Transporter 2 Mediates tubular uptake of organic compounds from circulation
SLC22A3 Solute Carrier Family 22 Member 3 OCT3 Organic Cation Transporter 3 Mediates potential-dependent transport of a variety of organic
cations
SLC22A4 Solute Carrier Family 22 Member 4 OCTN1 Organic Cation/Carnitine Transporter
1
Sodium-ion dependent, low affinity carnitine transporter
SLC22A5 Solute Carrier Family 22 Member 5 OCTN2 Organic Cation/Carnitine Transporter
2
Sodium-ion dependent, high affinity carnitine transporter
SLC22A6 Solute Carrier Family 22 Member 6 OAT1 Organic Anion Transporter 1 Involved in the renal elimination of endogenous and exogenous
organic anions
SLC22A7 Solute Carrier Family 22 Member 7 OAT2 Organic Anion Transporter 2 Mediates sodium-independent multispecific organic anion transport
SLC22A8 Solute Carrier Family 22 Member 8 OAT3 Organic Anion Transporter 3 Plays an important role in the excretion/detoxification of endogenous
and exogenous organic anions, especially from the brain and
kidney
SLC22A9 Solute Carrier Family 22 Member 9 OAT7 Organic Anion Transporter 7 Sodium-independent organic anion transporter which exhibits high
specificity for sulfated conjugates of xenobiotics and steroid
hormones
SLC22A11 Solute Carrier Family 22 Member 11 OAT4 Organic Anion Transporter 4 Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone
sulfate and related compounds



























































Supplementary Table 2 (Continued)
Suppl Table 2
Gene name Full gene name Protein name Full protein name Function (as defined by UniProtKB/Swiss-Prot)
SLC22A12 Solute Carrier Family 22 Member 12 URAT1 Urate Transporter 1 Required for efficient urate re-absorption in the kidney
SLC22A13 Solute Carrier Family 22 Member 13 OAT10 Organic Cation Transporter-Like 3 n.a.
SLC22A14 Solute Carrier Family 22 Member 14 OCTL2 Organic Cation Transporter-Like 4 n.a.
SLC22A15 Solute Carrier Family 22 Member 15 FLIPT1 Fly-Like Putative Transporter 1 Probably transports organic cations (By similarity)
SLC22A16 Solute Carrier Family 22 Member 16 OCT6 Organic Cation Transporter 6 Partially sodium-ion dependent, high affinity carnitine transporter
SLC22A17 Solute Carrier Family 22 Member 17 BOIT Potent Brain Type Organic Ion
Transporter
Cell surface receptor for LCN2 (24p3) that plays a key role in iron
homeostasis and transport
SLC22A18 Solute Carrier Family 22 Member 18 ORCTL2 Organic Cation Transporter-Like Pro-
tein 2
May act as a transporter of organic cations based on a proton efflux
antiport mechanism
SLC22A18AS Solute Carrier Family 22 Member 18
Antisense
SLC27A1 Solute Carrier Family 27 Member 1 FATP1 Fatty Acid Transport Protein 1 Mediates the ATP-dependent import of long-chain fatty acids
(LCFA) into the cell
SLC28A1 Solute Carrier Family 28 Member 1 CNT1 Concentrative Nucleoside Transporter
1
Sodium-dependent and pyrimidine-selective transporter
SLC28A2 Solute Carrier Family 28 Member 2 CNT2 Concentrative Nucleoside Transporter
2
Sodium-dependent and purine-selective transporter
SLC28A3 Solute Carrier Family 28 Member 3 CNT3 Concentrative Nucleoside Transporter
3
Sodium-dependent, pyrimidine- and purine-selective transporter
SLC29A1 Solute Carrier Family 29 Member 1 ENT1 Equilibrative Nucleoside Transporter
1
Mediates both influx and efflux of nucleosides across the membrane
(equilibrative transporter)
SLC29A2 Solute Carrier Family 29 Member 2 ENT2 Equilibrative Nucleoside Transporter
2
Mediates equilibrative transport of purine, pyrimidine nucleosides
and the purine base hypoxanthine
SLC29A3 Solute Carrier Family 29 Member 3 ENT3 Equilibrative Nucleoside Transporter
3
Mediates both influx and efflux of nucleosides across the membrane
(equilibrative transporter)
SLC29A4 Solute Carrier Family 29 Member 4 PMAT Plasma Membrane Monoamine
Transporter
Polyspecific organic cation transporter
SLC47A1 Solute Carrier Family 47 Member 1 MATE1 Multidrug And Toxin Extrusion Pro-
tein 1
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phe-
nylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN),
metformin, creatinine, guanidine, procainamide, topotecan, estrone
sulfate, acyclovir, ganciclovir and also the zwitterionic cephalo-
sporin, cephalexin and cephradin
SLC47A2 Solute Carrier Family 47 Member 2 MATE2 Multidrug And Toxin Extrusion Pro-
tein 2
Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phe-
nylpyridinium (MPP), cimetidine, N-methylnicotinamide, metfor-
min, creatinine, guanidine, procainamide, topotecan, estrone
sulfate, acyclovir, and ganciclovir
SLCO1A2 Solute Carrier Organic Anion Trans-
porter Family Member 1A2
OATP1A2 Organic Anion-Transporting Polypep-
tide 1
Mediates the Na(+)-independent transport of organic anions
SLCO1B1 Solute Carrier Organic Anion Trans-
porter Family Member 1B1
OATP1B1 Liver-Specific Organic Anion Trans-
porter 1
Mediates the Na(+)-independent uptake of organic anions
SLCO1B3 Solute Carrier Organic Anion Trans-
porter Family Member 1B3
OATP1B3 Liver-Specific Organic Anion Trans-
porter 2
Mediates the Na(+)-independent uptake of organic anions
SLCO1C1 Solute Carrier Organic Anion Trans-
porter Family Member 1C1
OATP1C1 Organic Anion Transporter Polypep-
tide-Related Protein 5
Mediates the Na(+)-independent high affinity transport of organic
anions



























































Supplementary Table 2 (Continued)
Suppl Table 2
Gene name Full gene name Protein name Full protein name Function (as defined by UniProtKB/Swiss-Prot)
SLCO2A1 Solute Carrier Organic Anion Trans-
porter Family Member 2A1
PGT Prostaglandin Transporter May mediate the release of newly synthesized prostaglandins from
cells
SLCO2B1 Solute Carrier Organic Anion Trans-
porter Family Member 2B1
OATP2B1 Organic Anion Transporter Polypep-
tide-Related Protein 2
Mediates the Na(+)-independent transport of organic anions
SLCO3A1 Solute Carrier Organic Anion Trans-
porter Family Member 3A1
OATP3A1 Organic Anion Transporter Polypep-
tide-Related Protein 3
Mediates the Na(+)-independent transport of organic anions
SLCO4A1 Solute Carrier Organic Anion Trans-
porter Family Member 4A1
OATP4A1 Organic Anion Transporter Polypep-
tide-Related Protein 1
Mediates the Na(+)-independent transport of organic anions
SLCO4C1 Solute Carrier Organic Anion Trans-
porter Family Member 4C1
OATP4C1 Organic Anion Transporter M1 Organic anion transporter, capable of transporting pharmacological
substances such as digoxin, ouabain, thyroxine, methotrexate and
cAMP
SLCO5A1 Solute Carrier Organic Anion Trans-
porter Family Member 5A1
OATP5A1 Organic Anion Transporter Polypep-
tide-Related Protein 4
n.a.
SLCO6A1 Solute Carrier Organic Anion Trans-
porter Family Member 6A1
OATP6A1 Testis-Specific Organic Anion
Transporter
n.a.
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